Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia

NCT05199909 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Antiphospholipid Syndrome
Thrombocytopenia
Treatment

Interventions

DRUG: zanubrutinib

Sponsor

Institute of Hematology & Blood Diseases Hospital, China